top of page


MEDSIR to present results of two of our research projects this year at ESMO 2020!

Updated: Dec 7, 2022

The European Society for Medical Oncology (ESMO) is the leading organization for medical oncology in Europe and has over 25,000 members from over 160 countries worldwide. Though virtual, this will still be considered as an invaluable platform to present promising new developments aimed at improving cancer patient care.

At this year’s conference, MEDSIR is presenting the results from two of our research projects: TRANSFAL and EXCAAPE, for breast and prostate cancer patients, respectively.

The PARSIFAL trial was a multicenter, randomized, open-label phase II study that explored the optimal endocrine agent to combine with palbociclib, either fulvestrant or letrozole, as initial therapy for patients with endocrine-sensitive, ER[+]/HER2[-] advanced breast cancer (ABC).

On Friday, September 18th, Dr. Marta Palafox, a postdoctoral researcher on the team of Dr. Violeta Serra at the Vall d’Hebron Institute of Oncology in Barcelona, is scheduled present the initial results of their research on the establishment of clinical trial-matched patient-derived xenografts (PDX) for translational studies. This research is part of the sub-study TRANSFAL, derived from MedSIR’s sponsored PARSIFAL trial.

To watch Dr. Palafox, please refer to ESMO’s website, presentation number 1933MO-TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies.

Additionally, Dr. Joan Carles Galcerán, Section Chief from the Oncology Department at the Vall d’Hebron Institute of Oncology in Barcelona, led the EXCAAPE study, a multicenter, single-arm, open-label, non-controlled phase IIa clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide.

A total of 52 patients were recruited from 9 participating hospitals in Spain and treated with Radium-223 (223Ra). The main study objectives were to assess the activity and safety of 223Ra in mCRPC patients, and to analyze the association between (Androgen Receptor splice variant 7 (AR-V7) status and response to treatment with 223Ra.

Our EXCAAPE ePoster will be available the 17th of September, please refer to the ESMO’S website presentation number 639P-223Ra to view it.

Details on the two MedSIR studies presented at #ESMO2020:

“TransFAL, PDXs for translational studies”

Abstract Title: TransFAL: Establishment of clinical trial-matched luminal breast cancer Patient-Derived Xenografts (PDX) for translational studies

Category: Translational Research (agnostic)

Abstract ID: #4288


Abstract Title: 223Ra in asymptomatic patients (pts) with metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed to 1st line abiraterone acetate or enzalutamide

Category: Genitourinary tumours, prostate

Abstract ID: #4176

If you would like to know more about these clinical trials (or others), do not hesitate to get in touch with us.



bottom of page